| Date |
Title |
|
|
04/18/19
|
Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results
|
|
|
04/09/19
|
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
|
|
|
04/08/19
|
Alkermes Announces Departure of Jim Robinson
|
|
|
04/03/19
|
Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
|
|
|
04/01/19
|
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
|
|
|
03/21/19
|
Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
|
|
|
03/05/19
|
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference
|
|
|
02/26/19
|
Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors
|
|
|
02/25/19
|
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
|
|
|
02/20/19
|
Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference
|
|
|
02/19/19
|
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
|
|
|
02/14/19
|
Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
|
|
|
02/07/19
|
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results
|
|
|
02/01/19
|
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
|
|
|
01/16/19
|
Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
|
|
